Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Altebrel (anti-TNF) for hospitalized adults with COVID-19
IRCT20200312046749N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Altebrel in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Improvement of pulmonary manifestations and duration, Radiologic improvement and 6 more. Started Mar 2020; status: completed.
02
Drugs
Altebrel
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200312046749N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200312046749N1.